[{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TAVO-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Tavotek Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tavotek Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tavotek Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tavaborole","moa":"Leucine-tRNA ligase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tavotek Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tavotek Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tavotek Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TAVO101","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tavotek Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tavotek Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tavotek Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"YuanBio Venture Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"Tavo111","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tavotek Biotherapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Tavotek Biotherapeutics \/ YuanBio Venture Capital","highestDevelopmentStatusID":"4","companyTruncated":"Tavotek Biotherapeutics \/ YuanBio Venture Capital"},{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Tavotek Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tavotek Biotherapeutics \/ Tavotek Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Tavotek Biotherapeutics \/ Tavotek Biotherapeutics"},{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TAVO412","moa":"EGFR\/VEGF\/c-Met","graph1":"Oncology","graph2":"Phase I","graph3":"Tavotek Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tavotek Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tavotek Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"TAVO412","moa":"EGFR\/VEGF\/c-Met","graph1":"Oncology","graph2":"Phase I","graph3":"Tavotek Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tavotek Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tavotek Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"Yisheng Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Tavo-201","moa":"||CD4 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Tavotek Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tavotek Biotherapeutics \/ Yisheng Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Tavotek Biotherapeutics \/ Yisheng Biopharma"}]

Find Clinical Drug Pipeline Developments & Deals by Tavotek Biotherapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          January 07, 2025

                          Lead Product(s) : TAVO412

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 19, 2023

                          Lead Product(s) : TAVO-101

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 21, 2022

                          Lead Product(s) : TAVO412

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 06, 2022

                          Lead Product(s) : Tavaborole

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 28, 2022

                          Lead Product(s) : TAVO101

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : The two rounds of financing will be used to accelerate the CMC production and IND filings of three antibody drugs (Tavo111, Tavo103, and Tavo101) developed by the company based on its TavoPrecise antibody platform.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          March 22, 2021

                          Lead Product(s) : Tavo111

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : YuanBio Venture Capital

                          Deal Size : $20.0 million

                          Deal Type : Series A Financing

                          blank

                          07

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : The objective of the alliance is to co-develop a combination therapy of involving Yisheng's & Tavotek's lead assets YS-ON-001/002 and Tavo-201/203 for cancer treatment.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 01, 2020

                          Lead Product(s) : YS-ON-001,Tavo-201,YS-ON-002

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Yisheng Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : The objective of the agreement is to develop a novel first-in-class immune-modulator bispecific antibody for auto-immune and inflammatory-related conditions, using DuoBody® technology, proprietary platform of Genmab A/S of Denmark.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 25, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Recipient : Genmab

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank